Abstract：
UNASSIGNED: Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact.
UNASSIGNED: To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI).
UNASSIGNED: A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022.
UNASSIGNED: Of all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss.
UNASSIGNED: This eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity.
UNASSIGNED: To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI).
UNASSIGNED: A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022.
UNASSIGNED: Of all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss.
UNASSIGNED: This eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity.
摘要：
■目前斑秃（AA）严重程度的措施，如脱发工具的严重程度评分，不能充分捕捉整体疾病的影响。
■为了探索头皮脱发以外与AA严重程度相关的因素，并支持斑秃严重程度和发病率指数（ASAMI）的发展。
■来自多个大洲的74名头发和头皮疾病专家被邀请参加一个由3轮调查组成的eDelphi项目。前两个会议是在Delphi研究设计之后通过基于文本的Web应用程序进行的。最后一轮几乎在2022年4月30日通过视频会议软件在参与者中进行。
■在所有受邀专家中，64人完成了第一轮调查(全球代表性：非洲[4.7%]，亚洲[9.4%]，澳大利亚[14.1%]，欧洲[43.8%]，北美[23.4%]，和南美[4.7%]；医疗保健环境：公共[20.3%]，私人[28.1%]，和两者[51.6%]）。共有58名专家完成了第二轮比赛,42人参加了最后的视频会议。总的来说,在107个问题中，有96个达成了共识。几个因素,与脱发工具的严重程度无关，被确定为可能恶化AA严重程度的结果。这些因素包括12个月或更长时间的疾病持续时间，3次或更多次复发，对局部或全身治疗的反应不足，快速的疾病进展，化妆上难以掩盖脱发，面部毛发受累(眉毛，睫毛,和/或胡须)，指甲受累，生活质量受损，有焦虑史,抑郁症,或由AA引起或加剧的自杀意念。达成共识，斑秃研究者全球评估量表对头皮脱发的严重程度进行了充分分类。
■这项eDelphi调查研究，在全球专家的共识下，确定了AA严重程度的各种决定因素，不仅包括头皮脱发，还包括其他结果。这些发现有望促进多组分严重性工具的开发，该工具可以有效地测量各种疾病的影响。这些发现也有望帮助确定当前和新出现的系统性治疗的候选人。未来的研究必须纳入患者和公众的观点，以将权重分配给本项目中与AA严重程度相关的领域。
■为了探索头皮脱发以外与AA严重程度相关的因素，并支持斑秃严重程度和发病率指数（ASAMI）的发展。
■来自多个大洲的74名头发和头皮疾病专家被邀请参加一个由3轮调查组成的eDelphi项目。前两个会议是在Delphi研究设计之后通过基于文本的Web应用程序进行的。最后一轮几乎在2022年4月30日通过视频会议软件在参与者中进行。
■在所有受邀专家中，64人完成了第一轮调查(全球代表性：非洲[4.7%]，亚洲[9.4%]，澳大利亚[14.1%]，欧洲[43.8%]，北美[23.4%]，和南美[4.7%]；医疗保健环境：公共[20.3%]，私人[28.1%]，和两者[51.6%]）。共有58名专家完成了第二轮比赛,42人参加了最后的视频会议。总的来说,在107个问题中，有96个达成了共识。几个因素,与脱发工具的严重程度无关，被确定为可能恶化AA严重程度的结果。这些因素包括12个月或更长时间的疾病持续时间，3次或更多次复发，对局部或全身治疗的反应不足，快速的疾病进展，化妆上难以掩盖脱发，面部毛发受累(眉毛，睫毛,和/或胡须)，指甲受累，生活质量受损，有焦虑史,抑郁症,或由AA引起或加剧的自杀意念。达成共识，斑秃研究者全球评估量表对头皮脱发的严重程度进行了充分分类。
■这项eDelphi调查研究，在全球专家的共识下，确定了AA严重程度的各种决定因素，不仅包括头皮脱发，还包括其他结果。这些发现有望促进多组分严重性工具的开发，该工具可以有效地测量各种疾病的影响。这些发现也有望帮助确定当前和新出现的系统性治疗的候选人。未来的研究必须纳入患者和公众的观点，以将权重分配给本项目中与AA严重程度相关的领域。
